Publication date: August 2026 Source: Blood Neoplasia, Volume 3, Issue 3 Author(s): Andrew J. Menssen, Amenech B. Ashango, Todd A. Alonzo, Robert B. Gerbing, Laura Pardo, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, Todd M. Cooper, Jessica A. Pollard, Katherine Tarlock, Richard Aplenc, Soheil Meshinchi, Lisa Eidenschink Brodersen, Denise A. Wells, Michael R. Loken, Chad A. Hudson
FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy. // Blood Neoplasia. – URL: https://www.sciencedirect.com/science/article/pii/S2950328026000798?dgcid=rss_sd_all
FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy. Blood Neoplasia. https://www.sciencedirect.com/science/article/pii/S2950328026000798?dgcid=rss_sd_all
“FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy.” Blood Neoplasia.
@article{article99801,
title = {FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy},
journal = {Blood Neoplasia},
url = {https://www.sciencedirect.com/science/article/pii/S2950328026000798?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment